Asia Pacific Cancer Monoclonal Antibodies Market Size & Outlook

The cancer monoclonal antibodies market in Asia Pacific is expected to reach a projected revenue of US$ 94,435.3 million by 2030. A compound annual growth rate of 12.1% is expected of Asia Pacific cancer monoclonal antibodies market from 2024 to 2030.
Revenue, 2023 (US$M)
$42,371.6
Forecast, 2030 (US$M)
$94,435.3
CAGR, 2024 - 2030
12.1%
Report Coverage
Asia Pacific

Asia Pacific cancer monoclonal antibodies market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Asia Pacific cancer monoclonal antibodies market, 2018-2030 (US$M)

Asia Pacific cancer monoclonal antibodies market highlights

  • The Asia Pacific cancer monoclonal antibodies market generated a revenue of USD 42,371.6 million in 2023.
  • The market is expected to grow at a CAGR of 12.1% from 2024 to 2030.
  • In terms of segment, human was the largest revenue generating source in 2023.
  • Humanized is the most lucrative source segment registering the fastest growth during the forecast period.
  • Country-wise, India is expected to register the highest CAGR from 2024 to 2030.


Asia Pacific data book summary

Market revenue in 2023USD 42,371.6 million
Market revenue in 2030USD 94,435.3 million
Growth rate12.1% (CAGR from 2023 to 2030)
Largest segmentHuman
Fastest growing segmentHumanized
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationHuman, Humanized, Chimeric, Murine
Key market players worldwideNovartis AG ADR, Pfizer Inc, GlaxoSmithKline Consumer Healthcare (GSK CH India), GlaxoSmithKline, Amgen Inc, Merck & Co Inc, Daiichi Sankyo Co Ltd, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Co, Johnson & Johnson, Bayer AG, Bristol-Myers Squibb Co, Roche Holding AG, Viatris Inc, Biogen Inc, Thermo Fisher Scientific Inc, Novo Nordisk A/S ADR, Sanofi SA, Merck KGaA


Other key industry trends

  • In terms of revenue, Asia Pacific region accounted for 17.8% of the global cancer monoclonal antibodies market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 94,435.3 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cancer Monoclonal Antibodies Market Scope

Cancer monoclonal antibodies market segmentation & scope
Pharmaceutical And Biotechnology Companies
Diagnostic Centers
Pharmaceutical And Biotechnology Companies
Diagnostic Centers
Pharmaceutical And Biotechnology Companies
Diagnostic Centers
Pharmaceutical And Biotechnology Companies
Diagnostic Centers
Rabbits
End Use
Specialty Centers
Hospitals
Academic And Research Centers
Pharmaceutical And Biotechnology Companies
Diagnostic Centers
Goats
End Use
Specialty Centers
Hospitals
Academic And Research Centers
Pharmaceutical And Biotechnology Companies
Diagnostic Centers
Sheep
End Use
Specialty Centers
Hospitals
Academic And Research Centers
Pharmaceutical And Biotechnology Companies
Diagnostic Centers
Mouse
End Use
Specialty Centers
Hospitals
Academic And Research Centers
Pharmaceutical And Biotechnology Companies
Diagnostic Centers
Others
End Use
Specialty Centers
Hospitals
Academic And Research Centers
Pharmaceutical And Biotechnology Companies
Diagnostic Centers

Cancer Monoclonal Antibodies Market Companies

Name Profile # Employees HQ Website

Asia Pacific cancer monoclonal antibodies market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer monoclonal antibodies market will help companies and investors design strategic landscapes.


Human was the largest segment with a revenue share of 55.79% in 2023. Horizon Databook has segmented the Asia Pacific cancer monoclonal antibodies market based on human, humanized, chimeric, murine covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Asia Pacific cancer monoclonal antibodies market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Asia Pacific cancer monoclonal antibodies market databook

  • Our clientele includes a mix of cancer monoclonal antibodies market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific cancer monoclonal antibodies market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific cancer monoclonal antibodies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Asia Pacific Cancer Monoclonal Antibodies Market Outlook Share, 2023 & 2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more